SEC Filing: Amgen, Onyx face Sept. 23 deadline for US antitrust decision
MLex Summary: Biotechnology company Amgen and fellow Nasdaq-listed Oynx Pharmaceuticals filed paperwork seeking US antitrust approval for their planned $10.4 billion tie-up on Sept. 6, giving regulators until Sept. 23 to...To view the full article, register now.
Already a subscriber? Click here to view full article